X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ACTAVIS
Dec-14
ALKEM LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,58917,418-   
Low Rs1,23210,625-   
Sales per share (Unadj.) Rs417.53,136.6-  
Earnings per share (Unadj.) Rs56.3-391.4-  
Cash flow per share (Unadj.) Rs64.7287.8-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.96,803.1-  
Shares outstanding (eoy) m119.57265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.5 75.6%   
Avg P/E ratio x25.1-35.8 -69.9%  
P/CF ratio (eoy) x21.848.7 44.7%  
Price / Book Value ratio x4.82.1 233.6%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6533,728,306 4.5%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m9,1710-   
Avg. sales/employee Rs ThNM38,611.5-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,818.3-  
INCOME DATA
Net Sales Rs m49,915834,009 6.0%  
Other income Rs m1,645-2,082 -79.0%   
Total revenues Rs m51,561831,927 6.2%   
Gross profit Rs m8,482107,140 7.9%  
Depreciation Rs m1,006180,593 0.6%   
Interest Rs m67126,306 2.5%   
Profit before tax Rs m8,451-101,841 -8.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,470 0.0%   
Tax Rs m1,606-5,236 -30.7%   
Profit after tax Rs m6,731-104,076 -6.5%  
Gross profit margin %17.012.8 132.3%  
Effective tax rate %19.05.1 369.6%   
Net profit margin %13.5-12.5 -108.1%  
BALANCE SHEET DATA
Current assets Rs m27,062439,416 6.2%   
Current liabilities Rs m15,324320,463 4.8%   
Net working cap to sales %23.514.3 164.9%  
Current ratio x1.81.4 128.8%  
Inventory Days Days6758 114.6%  
Debtors Days Days4166 62.3%  
Net fixed assets Rs m12,610101,841 12.4%   
Share capital Rs m2390-   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,0271,808,934 1.9%   
Long term debt Rs m1,212947,917 0.1%   
Total assets Rs m54,3873,315,181 1.6%  
Interest coverage x13.6-2.9 -473.7%   
Debt to equity ratio x00.5 6.6%  
Sales to assets ratio x0.90.3 364.8%   
Return on assets %13.6-2.3 -580.2%  
Return on equity %19.2-5.8 -334.0%  
Return on capital %24.9-3.0 -825.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,259143,216 5.1%  
From Investments Rs m1,864-342,913 -0.5%  
From Financial Activity Rs m-9,273192,667 -4.8%  
Net Cashflow Rs m-150-7,030 2.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare ALKEM LABORATORIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: ORCHID PHARMA LTD  IPCA LABS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  SHASUN PHARMA  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 22, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS